A Concordance Study Among 26 NGS Laboratories Participating in the National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH) Clinical Trial.
Zane LK, Yee LM, Chang TC, Sklar J, Yang G, Wen JD, Li P, Harrington R, Sims DJ, Harper K, Trent JM, LoBello JR, Szelinger S, Benson K, Zeng J, Poorman K, Xu D, Frampton GM, Pavlick DC, Miller VA, Tandon B, Swat W, Weiss L, Funari VA, Conroy JM, Prescott JL, Chandra PK, Ma C, Champion KJ, Baschkopf GX, Fesko YA, Freitas TAK, Tomlins SA, Hovelson DH, White K, Sorrells S, Tell R, Beaubier N, King D, Li L, Kelly K, Uvalic J, Meyers B, Kolhe R, Lindeman NI, Baltay M, Sholl LM, Lopategui J, Vail E, Zhang W, Telatar M, Afkhami M, Hsiao SJ, Mansukhani MM, Adams E, Jiang L, Aldape KD, Raffeld M, Xi L, Stehr H, Segal JP, Aisner DL, Davies KD, Brown NA, Livingston RJ, Konnick EQ, Song W, Solomon JP, Walther Z, McShane LM, Harris LN, Chen AP, Tsongalis GJ, Hamilton SR, Flaherty KT, O'Dwyer PJ, Conley BA, Patton DR, Iafrate AJ, Williams PM, Tricoli JV, Karlovich C.
Zane LK, et al. Among authors: hamilton sr.
Clin Cancer Res. 2025 Jun 4. doi: 10.1158/1078-0432.CCR-24-2188. Online ahead of print.
Clin Cancer Res. 2025.
PMID: 40465838